首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1290408

全球卵泡刺激素市場 - 2023-2030年

Global Follicle Stimulating Hormone Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球促卵泡激素市場在2022年達到19億美元，預計到2030年將見證有利可圖的成長，達到29億美元。在預測期內（2023-2030年），全球促卵泡激素市場預計將呈現5.8%的複合成長率。不孕不育症的發病率越來越高，人們對生育治療的認知和接受程度越來越高，以及人口老齡化的加劇，都推動了促卵泡激素市場的成長趨勢。

近年來，全球促卵泡激素（FSH）市場一直在不斷擴大。 FSH是一種生殖激素，對調節月經週期和鼓勵婦女卵巢卵泡的生長至關重要。它通常被用於生育治療和荷爾蒙替代療法。

全球促卵泡激素市場範圍包括重組FSH、尿液FSH、不孕不育治療、輔助生殖技術和其他組成部分，這增加了促卵泡激素市場佔有率的使用。全球促卵泡激素市場正在擴大，原因包括生育治療程序的技術進步，對生育治療的認知和接受程度的提高，以及對生殖健康的日益重視。

市場動態

老齡化人口的增加推動促卵泡激素市場的成長

全球FSH市場正受到人口老齡化的推動。個人的生育潛力隨著年齡的成長而降低，促使對生育治療的需求增加，特別是FSH治療，以解決與年齡相關的不孕不育。對生育治療的理解和接受程度的提高，以及推遲生育的趨勢，都促進了市場的上升。

例如，根據世界衛生組織（WHO）2022年的報告，到2030年，地球上每六個人中就有一個人是60歲或以上。在這個時間跨度內，60歲及以上的世界人口比例預計將從2020年的10億增加到14億。總的來說，老齡人口對生育的渴望和對生育解決方案的需求推動了全球促卵泡激素市場的成長。

擴大採用輔助生殖技術是全球卵泡刺激素市場的主要驅動力

輔助生殖技術（ART）的使用包括各種醫療技術，旨在幫助個人實現懷孕。體外受精（IVF）是最著名的ART類型之一，其中卵子和精子在實驗室環境中混合受精，然後將產生的胚胎植入子宮內。

此外，多囊卵巢綜合症（PCOS）患病率的上升也促使了不孕症的增加。根據美國疾病控制和預防中心（CDC）2022年的統計數據，多囊卵巢綜合症是女性不孕的一個常見原因，大約影響美國6%至12%的育齡婦女。多囊卵巢綜合症的持續流行將推動對不孕症治療的需求，從而在預測期內推動全球促卵激素市場的發展。

由於不孕不育的挑戰和對輔助生殖技術的需求，個人的情緒和心理受到嚴重影響，將阻礙市場的發展。

不孕不育和ART的社會心理後果是廣泛的，它們會對患者的自我認同感和個人機構、精神健康、性和婚姻關係、生殖效率、治療依從性和懷孕結果產生重大影響。 25%至65%的接受抗逆轉錄病毒療法的婦女會經歷臨床壓力、焦慮和負面情緒，如低自尊或內疚。因此，上述因素限制了促卵泡激素市場的發展。

COVID-19影響分析

世界上許多國家的COVID-19大流行和封鎖，使各行業公司的財務健康受到影響。因此，在COVID-19公共衛生緊急情況期間，美國食品和藥物管理局（FDA）發布了指導方針，其中包括幫助贊助商和研究人員的一般注意事項，確保試驗參與者的安全，堅持良好的臨床實踐（GCP），並儘量減少試驗完整性的風險。

俄烏戰爭影響分析

俄羅斯和烏克蘭之間的衝突有可能促使供應鏈的中斷、不確定性和不穩定，這可能會影響全球卵泡刺激素（FSH）市場。 FSH產品的開發和臨床試驗將受到影響，這將減緩創新。市場參與者可能會尋找FSH生產的多樣化和替代來源。

此外，定價和需求可能受到經濟影響，包括貨幣波動和市場動態的修改。可能會有區域差異，離衝突較近的國家會更快地感受到影響。為了駕馭潛在的障礙並抓住FSH市場的可能性，行業利益相關者必須保持持續的觀察和靈活性。

Market Overview

The Global Follicle Stimulating Hormone Market reached US$ 1.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.9 billion by 2030. The global follicle stimulating hormone market is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030). The increasing prevalence of infertility, growing awareness and acceptance of fertility treatments, and growing aging population are driving the growth of the follicle stimulating hormone market trends.

The global follicle stimulating hormone (FSH) market has been expanding continuously in recent years. FSH, a reproductive hormone, is essential in regulating the menstrual cycle and encouraging the growth of ovarian follicles in women. It is commonly utilized in fertility treatments and hormone replacement therapies.

The global follicle stimulating hormone market scope comprises components encompassing recombinant FSH, urinary FSH, infertility treatment, assisted reproductive technology and others, which has increased usage of follicle stimulating hormone market share. The global market for follicle stimulating hormones is expanding as a result of factors including technological advancements in fertility treatment procedures, increasing awareness and acceptance of fertility treatments, and increasing focus on reproductive health.

Market Dynamics

An Increase in Aging Population Drive the Growth of the Follicle Stimulating Hormone Market

The global FSH market is being driven by an aging population. Individuals' fertility potential reduces as they age, resulting in an increased demand for fertility treatments, especially FSH treatment, to address age-related infertility. The increased understanding and acceptability of fertility treatments, as well as the trend of postponed childbirth, have all contributed to the market's rise.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. Overall, the aging population's desire for parenthood and the need for fertility solutions drive the growth of the global follicle stimulating hormone market.

Growing Adoption of Assisted Reproductive Technology is the Major Driver in the Global Follicle Stimulating Hormone Market

The use of assisted reproductive technology (ART) includes a variety of medical techniques designed to aid individuals in achieving pregnancy. In vitro fertilization (IVF) is one of the most well-known types of ART, in which eggs and sperm are mixed in a laboratory setting to fertilize and then implant the resulting embryos into the uterus.

Furthermore, the rising prevalence of polycystic ovary syndrome (PCOS) has contributed to an increase in infertility. PCOS is a common cause of female infertility, affecting roughly 6% to 12% of women of reproductive age in the United States, according to the Centers for Disease Control and Prevention (CDC) 2022 statistics. The continued prevalence of PCOS will drive demand for infertility treatments, consequently propelling the global follicle stimulating hormone market over the forecast period.

Significant Emotional and Psychological Toll on Individuals Due to Fertility Challenges and the Need for Assisted Reproductive Technologies Will Hamper the Growth of the Market.

The psychosocial consequences of infertility and ART are extensive, and they can have a significant impact on patients' sense of self-identity and personal agency, mental well-being, sexual and marital relationships, reproductive efficiency, treatment compliance, and pregnancy outcomes. Between 25% and 65% of women receiving ART experience clinical stress, anxiety, and negative emotions such as low self-esteem or guilt. Hence, the above mentioned factors are limiting the follicle stimulating hormone market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The conflict between Russia and Ukraine has the potential to cause supply chain interruptions, uncertainty, and instability, which could affect the worldwide follicle-stimulating hormone (FSH) market. FSH product development and clinical trials would be impacted, which would slow down innovation. Market participants might look for FSH production diversification and alternate sources.

Furthermore, pricing and demand may be impacted by the economic impact, which includes currency fluctuations and modifications to market dynamics. There may be regional variances, with nations closer to the conflict feeling the effects more immediately. In order to navigate potential obstacles and seize possibilities in the FSH market, industry stakeholders must maintain constant observation and flexibility.

Segment Analysis

The global follicle stimulating hormone market is segmented based on type, application, end user, and region.

Recombinant FSH Segment Accounts for 56.3% of the Market Share Owing to Rising Demand for it.

Recombinant FSH products are produced in the laboratory and have various advantages over urinary-derived FSH products. One significant advantage is their superior purity, as they are free of contaminants commonly present in urinary-derived FSH. This provides consistent potency and reduces the possibility of contamination.

Gonal-f, Follistim, and Puregon are examples of rFSH medicines that have a sizable market share. Because of their effectiveness and high-quality standards, these brands have gained favor among healthcare providers and patients. They are trusted choices in reproductive treatments, including regulated ovarian stimulation in ART procedures such as IVF.

For instance, Bharat Serums and Vaccines Limited is conducting a clinical trial using Recombinant Human Follicle Stimulating Hormone for treating infertility. About 250 women in the age group of 20 to 39 years have participated in this trial and currently, it is in phase 3 trial and the estimated completion of the trial is in November 2023. Therefore, owing to the above reasons, the recombinant FSH segment is expected to drive the market growth over the forecast period.

Geographical Analysis

North America Accounted for Approximately 41.4% of the Market Share Owing to the Investment by the Major Players' Presence in this Region

North America's market dominance has been facilitated by the presence of established and influential companies, increased awareness and an increase in the rate of infertility growth which is related to unhealthy lifestyles and diets. Also, the rising healthcare costs and the widespread use of FSH products, along with an increase in inpatient visits to gynecologists are driving the market demand in North America.

Furthermore, Fertility Awareness Methods (FAMs), for example, are recognized by the United States Agency for International Development (USAID) as modern contraceptives that meet specified requirements, such as safety, effectiveness in preventing conception, and a basic grasp of reproductive biology.

FAMs have been evaluated in well-designed studies to determine their efficacy under a variety of situations. FAMs also have the advantage of not requiring clinical involvement and can be delivered through a variety of service delivery methods. As a result of the aforementioned factors, the North American region is expected to hold the biggest market share throughout the projection period.

Competitive Landscape

The major global players in the follicle stimulating hormone market include: Merck Serono, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions, Inc, and BIOGENIX INC.PVT.LTD.

Why Purchase the Report?

To visualize the global follicle stimulating hormone market segmentation based on type, application, end user and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Follicle stimulating hormone market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global follicle stimulating hormone market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. An Increase in Aging Population
  - 4.1.1.2. Growing Adoption of Assisted Reproductive Technology
- 4.1.2. Restraints
  - 4.1.2.1. Emotional and Psychological Toll on Individuals due to Fertility Challenges
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Recombinant FSH*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Urinary FSH

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Infertility Treatment*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Assisted Reproductive Technology (ART)
8.4. Others

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Infertility Center*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospitals
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Merck Serono*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Creative BioMart
12.3. Midas Pharma GmbH
12.4. GenPharm
12.5. Trumac Healthcare
12.6. Livzon
12.7. Shanghai Techwell Biopharmaceutical Co., Ltd.
12.8. Merck Sharp & Dohme Corp
12.9. Lee Biosolutions,Inc
12.10. BIOGENIX INC.PVT.LTD.

LIST NOT EXHAUSTIVE